93 related articles for article (PubMed ID: 26946358)
21. Interactions of prion protein with intracellular proteins: so many partners and no consequences?
Nieznanski K
Cell Mol Neurobiol; 2010 Jul; 30(5):653-66. PubMed ID: 20041289
[TBL] [Abstract][Full Text] [Related]
22. Preventing misfolding of the prion protein by trimethylamine N-oxide.
Bennion BJ; DeMarco ML; Daggett V
Biochemistry; 2004 Oct; 43(41):12955-63. PubMed ID: 15476389
[TBL] [Abstract][Full Text] [Related]
23. Identification of proteins with high affinity for refolded and native PrPC.
Petrakis S; Sklaviadis T
Proteomics; 2006 Dec; 6(24):6476-84. PubMed ID: 17111435
[TBL] [Abstract][Full Text] [Related]
24. Distribution of the cellular prion protein (PrPC) in brains of livestock and domesticated species.
Díaz-San Segundo F; Salguero FJ; de Avila A; Espinosa JC; Torres JM; Brun A
Acta Neuropathol; 2006 Nov; 112(5):587-95. PubMed ID: 16957924
[TBL] [Abstract][Full Text] [Related]
25. Electron paramagnetic resonance evidence for binding of Cu(2+) to the C-terminal domain of the murine prion protein.
Cereghetti GM; Schweiger A; Glockshuber R; Van Doorslaer S
Biophys J; 2001 Jul; 81(1):516-25. PubMed ID: 11423433
[TBL] [Abstract][Full Text] [Related]
26. Knockdown of prion protein (PrP) by RNA interference weakens the protective activity of wild-type PrP against copper ion and antagonizes the cytotoxicity of fCJD-associated PrP mutants in cultured cells.
Wang ZY; Tian C; Jing YY; Gong HS; Guo Y; Shi Q; Chen C; Zhu SY; Dong XP
Int J Mol Med; 2011 Sep; 28(3):413-21. PubMed ID: 21537833
[TBL] [Abstract][Full Text] [Related]
27. The N Terminus of the Prion Protein Mediates Functional Interactions with the Neuronal Cell Adhesion Molecule (NCAM) Fibronectin Domain.
Slapšak U; Salzano G; Amin L; Abskharon RN; Ilc G; Zupančič B; Biljan I; Plavec J; Giachin G; Legname G
J Biol Chem; 2016 Oct; 291(42):21857-21868. PubMed ID: 27535221
[TBL] [Abstract][Full Text] [Related]
28. Translocation of cellular prion protein to non-lipid rafts protects human prion-mediated neuronal damage.
Jeong JK; Moon MH; Lee YJ; Seol JW; Park SY
Int J Mol Med; 2012 Mar; 29(3):387-92. PubMed ID: 22179431
[TBL] [Abstract][Full Text] [Related]
29. A roadmap for investigating the role of the prion protein in depression associated with neurodegenerative disease.
Beckman D; Linden R
Prion; 2016 Mar; 10(2):131-42. PubMed ID: 27057694
[TBL] [Abstract][Full Text] [Related]
30. Amyloid-beta oligomers increase the localization of prion protein at the cell surface.
Caetano FA; Beraldo FH; Hajj GN; Guimaraes AL; Jürgensen S; Wasilewska-Sampaio AP; Hirata PH; Souza I; Machado CF; Wong DY; De Felice FG; Ferreira ST; Prado VF; Rylett RJ; Martins VR; Prado MA
J Neurochem; 2011 May; 117(3):538-53. PubMed ID: 21352228
[TBL] [Abstract][Full Text] [Related]
31. Essential role of the prion protein N terminus in subcellular trafficking and half-life of cellular prion protein.
Nunziante M; Gilch S; Schätzl HM
J Biol Chem; 2003 Feb; 278(6):3726-34. PubMed ID: 12431994
[TBL] [Abstract][Full Text] [Related]
32. Binding of neural cell adhesion molecules (N-CAMs) to the cellular prion protein.
Schmitt-Ulms G; Legname G; Baldwin MA; Ball HL; Bradon N; Bosque PJ; Crossin KL; Edelman GM; DeArmond SJ; Cohen FE; Prusiner SB
J Mol Biol; 2001 Dec; 314(5):1209-25. PubMed ID: 11743735
[TBL] [Abstract][Full Text] [Related]
33. The association between prion proteins and Aβ₁₋₄₂ oligomers in cytotoxicity and apoptosis.
Hyeon JW; Kim SY; Park JS; Choi BY; Lee SM; Ju YR; An SS; Kim CK
Biochem Biophys Res Commun; 2012 Jul; 424(2):214-20. PubMed ID: 22743555
[TBL] [Abstract][Full Text] [Related]
34. Monitoring prion protein stability by NMR.
Julien O; Graether SP; Sykes BD
J Toxicol Environ Health A; 2009; 72(17-18):1069-74. PubMed ID: 19697241
[TBL] [Abstract][Full Text] [Related]
35. P2X4 receptor in the dorsal horn partially contributes to brain-derived neurotrophic factor oversecretion and toll-like receptor-4 receptor activation associated with bone cancer pain.
Jin XH; Wang LN; Zuo JL; Yang JP; Liu SL
J Neurosci Res; 2014 Dec; 92(12):1690-702. PubMed ID: 24984884
[TBL] [Abstract][Full Text] [Related]
36. Screening a library of potential prion therapeutics against cellular prion proteins and insights into their mode of biological activities by surface plasmon resonance.
Touil F; Pratt S; Mutter R; Chen B
J Pharm Biomed Anal; 2006 Mar; 40(4):822-32. PubMed ID: 16242887
[TBL] [Abstract][Full Text] [Related]
37. Thermodynamic and spectroscopic investigation on the role of Met residues in Cu(II) binding to the non-octarepeat site of the human prion protein.
Remelli M; Valensin D; Toso L; Gralka E; Guerrini R; Marzola E; Kozłowski H
Metallomics; 2012 Aug; 4(8):794-806. PubMed ID: 22791135
[TBL] [Abstract][Full Text] [Related]
38. Regional and phenotype heterogeneity of cellular prion proteins in the human brain.
Kuczius T; Koch R; Keyvani K; Karch H; Grassi J; Groschup MH
Eur J Neurosci; 2007 May; 25(9):2649-55. PubMed ID: 17466020
[TBL] [Abstract][Full Text] [Related]
39. Review: membrane-associated misfolded protein propagation in natural transmissible spongiform encephalopathies (TSEs), synthetic prion diseases and Alzheimer's disease.
Jeffrey M
Neuropathol Appl Neurobiol; 2013 Apr; 39(3):196-216. PubMed ID: 23171056
[TBL] [Abstract][Full Text] [Related]
40. Fast, reversible interaction of prion protein with RNA aptamers containing specific sequence patterns.
Mercey R; Lantier I; Maurel MC; Grosclaude J; Lantier F; Marc D
Arch Virol; 2006 Nov; 151(11):2197-214. PubMed ID: 16799875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
